The pharmacological aspects of the treatment of acromegaly.
Giustina
A
A
Department of Internal Medicine, University of Brescia, Italy.
Zaltieri
G
G
Negrini
F
F
Wehrenberg
W B
WB
D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018491:Dopamine Agonists / Q000627:therapeutic use; D013006:Growth Hormone / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D015282:Octreotide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000473:pathology; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use
D018491:Dopamine Agonists; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide